A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy

Head and neck cancers (HNSCC) account for 5% of all cancers, and squamous cell carcinoma or a variant is the main histologic type in more than 90% of these tumors [1]. Single-modality treatment with surgery or radiotherapy is usually recommended for early disease (stage I or II). Due to complicated anatomy and the wide extension of local or regionally advanced disease, the combined treatment strategy of radical radiotherapy with chemotherapy or cetuximab [2] is a preferred option for unresectable disease.

Source: Oral Oncology - November 7, 2017 Category: Cancer & Oncology Authors: Hao Peng, Bin-Bin Chen, Lei Chen, Yu-Pei Chen, Xu Liu, Ling-Long Tang, Yan-Ping Mao, Wen-Fei Li, Yuan Zhang, Ai-Hua Lin, Ying Sun, Jun Ma Source Type: research